Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The multidisciplinary management of patients with Duchenne muscular dystrophy is discussed by experts Crystal Proud, MD, and Amy D. Harper, MD.
Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.
The findings support the advancement of a 100-mcg dose vaccine to a phase 3 trial assessment in later summer 2020, while a phase 2 trial of a pair of different doses continues among 600 healthy adults.
In the post hoc analysis from the phase 3 ASCLEPIOS I and II trials presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Annual Meeting, subcutaneous ofatumumab is compared with oral teriflunomide in relapsing multiple sclerosis.
The assistant professor of neurosurgery at Yale School of Medicine discussed the observations she and colleagues have made of the relationship between microglia and astrocytes in the cell death process.